The collaboration brings together complementary capabilities from each company, including Kite’s clinical development, manufacturing, supply chain and commercial leadership in engineered T-cell therapy and Vitruvian’s hybrid expertise in building cloud-based software and data analytics solutions in cell and gene therapy manufacturing and delivery settings.
“Kite’s technology and services, which will be known as Kite Konnect™, will directly shape the overall experience of patients, physicians, and treatment centers as engineered T-cell therapies potentially become available commercially,” said Tim Moore, Executive Vice President of Technical Operations for Kite. “We are committed to advanced solutions that improve speed and customer satisfaction, streamline logistics and ensure excellence for chain of identity and custody which is essential for safety and quality. Our strategic partnership with Vitruvian is a key component of our overall technology strategy and builds on our research collaboration with GE Global Research to automate manufacturing of engineered T-cell therapies.”
“We are honored to work with Kite to accelerate the design and development of Vitruvian Network’s cell and gene therapy software and data analytics platform,” said Amy DuRoss, Chief Executive Officer of Vitruvian Networks. “Companies like Kite, who sit on the leading edge of scientific innovation, require a cloud-based, design-led solution to ensure they have a safe, cost-effective, and easy-to-use platform to serve a growing number of patients who are desperate for these potentially lifesaving therapies. Our software and analytics solution will help Kite and other cell therapy producers deliver their treatments to more patients, expediting growth of the personalized medicine industry.”
Under the terms of the agreement, both parties will contribute resources and relevant experience to the partnership. Further terms of the agreement were not disclosed.
About axicabtagene ciloleucel
Kite Pharma’s lead product candidate, axicabtagene ciloleucel, is an investigational therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) regulatory support for DLBCL in the EU.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system’s ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at http://www.twitter.com/kitepharma.
About Vitruvian Networks
Vitruvian Networks was co-founded by GE Ventures and the Mayo Clinic to solve key challenges in the commercialization and delivery of cell and gene therapies. Vitruvian Networks’ suite of software solutions improves patient access, expedites life-changing treatment delivery, and promotes safety compliance for personalized cell therapies. The Vitruvian Networks platform addresses ordering, logistics, resource planning, mission control center, regulatory compliance, and customer service. Vitruvian Networks is based in San Francisco. For more information, please visit www.vineti.com. Sign up to follow @vinetiworks on https://twitter.com/vinetiworks.